Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Zetagen Therapeutics Secures $12.9M Series B1 Funding
Series BVenture Capital

Zetagen Therapeutics Secures $12.9M Series B1 Funding

•November 25, 2025
•Nov 25, 2025
0

Participants

Zetagen

Zetagen

company

JSTAR Capital

JSTAR Capital

investor

Why It Matters

The funding validates investor confidence in Zetagen’s novel delivery approach and provides resources to advance three breast‑cancer candidates, potentially reshaping treatment paradigms and creating a new market niche for intratumoral therapies.

Deal Summary

Zetagen Therapeutics announced the close of a $12.9 million Series B1 round, 100 % oversubscribed and led by JSTAR Capital Investments. The funding will support the development of its intratumoral breast cancer therapeutics platform.

0

Comments

Want to join the conversation?

Loading comments...